Sorrento Therapeutics Inc (SRNE): Only 2 trading days until Morgan Stanley...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Sorrento Therapeutics Inc (SRNE)

Reply Private New

Keep Last Read

Replies (3) Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5697
Boards Moderated	0
Alias Born	12/13/2004

Re: None

Friday, 09/09/2022 9:30:23 PM

Friday, September 09, 2022 9:30:23 PM

Only 2 trading days until Morgan Stanley 20th Annual Global Healthcare Conference.
Location: New York City
Dates: September 12 - 14, 2022
Company Presentation: September 14, 2022, at 8:00 am Eastern time
The August Corporate Presentation does seem to highlight ABIVERTINIB, Mpro, Virex and SEMDEXA.
But we know that beside these top 4 multibillion $ programs they are advancing many other high potential programs. e.g. PD-L1, ADNAB, DAR-T, RTX, SOFUSA!
My assumption is that the top 4 programs are closest to market...but it would be nice to also hear something about the others.
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (3) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM

More SRNE News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow